Jade Biosciences (JBIO) stock
JBIO · Jade Biosciences Inc. · NASDAQ
- Market cap
- $1.06B
- Shares out
- 69.2M
- Open
- $15.35
- Prev close
- $15.09
- VWAP
- $15.34
Today $15.20 - $15.50
What is the latest news on JBIO stock?
JBIO rose 1.46% to $15.31 on Nov 20, 2026. No JBIO story in the last two days; the most recent is below.
SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
All JBIO newsWhen does Jade Biosciences report earnings?
Jade Biosciences last reported on Jun 1, 2026, the date it announced on May 29, 2026.
JBIO earnings historyWho owns the most JBIO stock?
FMR LLC was the largest reported holder of JBIO at the end of Q2 2026, with 9,126,877 shares worth $202.8 million. Next came Jupiter Topco LLC ($139.4 million) and Fairmount Funds Management LLC ($101.2 million). In all, 154 institutions reported $1.6 billion of JBIO in their 13F filings.
All JBIO fund holdersFinancial highlights
Full financials- Net income, TTM
- -$163.12M
- Cash
- $80.39M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECSEC Form 10-Q filed by Jade Biosciences Inc.10-Q - Jade Biosciences, Inc. (0001798749) (Filer)
- SECJade Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateJADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027 JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE
- PRJade Biosciences to Participate in Upcoming ConferencesSAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceFireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ETLocation: Boston, MAStifel Healthcare ConferenceFireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ETLocation: New York, NYUBS Global Biopharma Conference Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMTLocation: London, UKJefferies Global H
- SECSEC Form SCHEDULE 13G filed by Jade Biosciences Inc.SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)
- PRJade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that three posters related to JADE101, a novel, ultra-high affinity and half-life extended investigational anti-A Pr
- SECSEC Form 8-K filed by Jade Biosciences Inc.8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosingJADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cellsFollowing subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscleJADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027Compa
- PRJade Biosciences to Participate in Upcoming ConferencesSAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m. ETCiti 2026 Biopharma Back to School Summit Fireside Chat: Wednesday, September 9 at 9:20 a.m. ETH.C. Wainwright 28th Annual Global Investment Conference Fireside Chat: Tuesday, September 15 at 1:00 p.m. ETStifel Virtual Immunology and Inflammation ForumFireside Chat: Wedn
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECSEC Form 10-Q filed by Jade Biosciences Inc.10-Q - Jade Biosciences, Inc. (0001798749) (Filer)
- SECJade Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAnnounced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027 JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 20
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECSEC Form 8-K filed by Jade Biosciences Inc.8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- INSIDERSEC Form 4 filed by Director Eisner Mark4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Eisner Mark3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECJade Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsSAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026. "We are pleased to welcome Dr. Eisner to the board," said Tom Frohlich, Chief Executive Officer of Jade Biosciences. "Mark’s biopharmaceutical executive experience and proven track record guiding innovative therapies from early clinical development through regulatory approval and global commercialization will be highly valuabl
- ANALYSTUBS initiated coverage on Jade Biosciences with a new price targetUBS initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $45.00
- INSIDERSEC Form 4 filed by Director Cain Christopher W.4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECSEC Form DEFA14A filed by Jade Biosciences Inc.DEFA14A - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other off
JBIO rankings
- Other4(40%)
- SEC Filings3(30%)
- Earnings2(20%)
- 13D/G1(10%)
Jade Biosciences Inc. (JBIO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for JBIO, including 2 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 16, 2026.
JBIO FAQ
8 questionsIs JBIO profitable?
No. Jade Biosciences Inc. reported a net loss of $163.12M for the twelve months ended Sep 30, 2026.How much cash and debt does JBIO have?
Jade Biosciences Inc. reported $80.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does JBIO stock trade?
Jade Biosciences Inc. (JBIO) is listed on NASDAQ.What sector and industry is JBIO in?
Jade Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Jade Biosciences Inc. go public?
Jade Biosciences Inc. (JBIO) completed its IPO in 2021.What are analysts saying about JBIO?
Across the last 8 analyst actions on Jade Biosciences Inc., there was 1 upgrade and 0 downgrades. The most recent action was from UBS: Buy with a $45.00 price target on 2026-06-15. Recent price targets range from $10.00 to $45.00.What companies are similar to JBIO?
Notable peers in the same industry include VNDA (Vanda Pharmaceuticals Inc.), TVTX (Travere Therapeutics Inc.), VERA (Vera Therapeutics Inc.). Compare JBIO side-by-side with any of them on Quantisnow.How can I track JBIO on Quantisnow?
Quantisnow aggregates Jade Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JBIO to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change